Interference of deferasirox with assays for serum iron and serum unsaturated iron binding capacity during iron chelating therapy.
Ikuta K, Ito S, Tanaka H, Sasaki K, Torimoto Y, Fujiya M, Kohgo Y
Purpose
The purpose of this paper was to determine the effects of the addition of the oral iron chelator deferasirox (DFX) on measured serum iron levels (sFe) and iron binding capacity (UIBC) using 4 different assay systems.
Conclusion
Adding up to 300 uM of iron-free DFX to pooled serum had no effects on the measurement of sFe using any of the 4 analyzer reagents. Adding iron-free DFX to pooled serum resulted in a concentration-dependent increase in UIBC for all analyzer reagents tested, but the increase was minimal (approximately 1%) using Ferene.
Studies (1)
Purpose
The purpose of this study was to determine the effects of the addition of the oral iron chelator DFX on measured sFe and UIBC using 4 different assay systems with the 7180 clinical analyzer. Serum was obtained from 4 different institutions. No details of handling or preservation were provided.
Summary of Findings
Adding up to 300 uM of iron-free DFX to pooled serum had no effects on the measurement of sFe using any of the 4 analyzer reagents. Adding iron-free DFX to pooled serum resulted in a concentration-dependent increase in UIBC for all analyzer reagents tested, but the increase was minimal (approximately 1%) using Ferene.
Biospecimens
FluidSerumPreservation Types
None (Fresh)Diagnoses
Not specifiedPlatforms
Electrolyte/MetalClinical chemistry/auto analyzerPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Biospecimen Aliquots and Components Biospecimen components 0 uM DFX120 uM DFX180 uM DFX240 uM DFX300 uM DFX60 uM DFXClinical chemistry/auto analyzer Specific Reaction solution BathophenanthrolineFereneFerroZineNitroso-PSAP